Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Innate Immune Responses to S. Typhi in Patients and Vaccinees
NCT03600025Phase 1Unknown
- Sponsor
- icddr,b
- Start
- Jul 2018
- Primary completion
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of typhoid conjugate vaccine in typhoid fever (2 arms), sponsored by icddr,b. Primary endpoints: Frequency of Mucosal Associated Invariant T (MAIT) cells and Natural Killer (NK) cells at 30 days, Roles of IL-21, IL-12, IL-15 and IL-18 in the activation of natural killer cells at 30 days and 1 more. Status: unknown.
02
Drugs
typhoid conjugate vaccine
03
Conditions
typhoid fever
Beyond the preview
Go deeper on NCT03600025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03600025.